DK1427420T3 - Anvendelse af en kombination indeholdende 4-pyridylmethyl-phthalaziner til cancerbehandling - Google Patents

Anvendelse af en kombination indeholdende 4-pyridylmethyl-phthalaziner til cancerbehandling

Info

Publication number
DK1427420T3
DK1427420T3 DK02779338T DK02779338T DK1427420T3 DK 1427420 T3 DK1427420 T3 DK 1427420T3 DK 02779338 T DK02779338 T DK 02779338T DK 02779338 T DK02779338 T DK 02779338T DK 1427420 T3 DK1427420 T3 DK 1427420T3
Authority
DK
Denmark
Prior art keywords
pyridylmethyl
phthalazines
cancer treatment
combination containing
phthalazine
Prior art date
Application number
DK02779338T
Other languages
Danish (da)
English (en)
Inventor
Margaret Han Dugan
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1427420T3 publication Critical patent/DK1427420T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02779338T 2001-09-12 2002-09-11 Anvendelse af en kombination indeholdende 4-pyridylmethyl-phthalaziner til cancerbehandling DK1427420T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33102501P 2001-09-12 2001-09-12
US31869401P 2001-09-12 2001-09-12
US32204401P 2001-09-14 2001-09-14
US38816302P 2002-06-12 2002-06-12

Publications (1)

Publication Number Publication Date
DK1427420T3 true DK1427420T3 (da) 2006-10-02

Family

ID=27502161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02779338T DK1427420T3 (da) 2001-09-12 2002-09-11 Anvendelse af en kombination indeholdende 4-pyridylmethyl-phthalaziner til cancerbehandling

Country Status (22)

Country Link
US (2) US20040258770A1 (no)
EP (1) EP1427420B1 (no)
JP (1) JP2005502690A (no)
KR (1) KR20040029172A (no)
CN (1) CN1330308C (no)
AT (2) ATE329597T1 (no)
AU (2) AU2002342678B2 (no)
BR (1) BR0212446A (no)
CA (1) CA2457848A1 (no)
CO (1) CO5560545A2 (no)
CY (1) CY1105189T1 (no)
DE (2) DE60231068D1 (no)
DK (1) DK1427420T3 (no)
ES (2) ES2320922T3 (no)
HR (1) HRP20040241A2 (no)
IL (1) IL160382A0 (no)
NO (1) NO327358B1 (no)
NZ (1) NZ531484A (no)
PL (1) PL367349A1 (no)
PT (1) PT1427420E (no)
RS (1) RS16804A (no)
WO (1) WO2003022282A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
EP1738752A1 (en) * 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmaceutical combinations comprising cis-retine acid
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
KR101037292B1 (ko) * 2010-09-03 2011-05-27 (주)슈추어 신발 장식구

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849741A (en) * 1994-08-09 1998-12-15 Eisai Co., Ltd. Fused pyridazine compounds
NZ331191A (en) * 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
US6096904A (en) * 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion

Also Published As

Publication number Publication date
US20040258770A1 (en) 2004-12-23
DE60212415T2 (de) 2006-11-23
PL367349A1 (en) 2005-02-21
ES2320922T3 (es) 2009-05-29
JP2005502690A (ja) 2005-01-27
NO327358B1 (no) 2009-06-15
BR0212446A (pt) 2004-08-17
KR20040029172A (ko) 2004-04-03
WO2003022282A1 (en) 2003-03-20
RS16804A (en) 2007-02-05
DE60212415D1 (de) 2006-07-27
CN1553803A (zh) 2004-12-08
AU2002342678B2 (en) 2006-08-24
US20090196871A1 (en) 2009-08-06
ATE421880T1 (de) 2009-02-15
EP1427420B1 (en) 2006-06-14
CN1330308C (zh) 2007-08-08
ES2266590T3 (es) 2007-03-01
ATE329597T1 (de) 2006-07-15
EP1427420A1 (en) 2004-06-16
NO20040973L (no) 2004-06-03
AU2006203428A1 (en) 2006-08-31
CO5560545A2 (es) 2005-09-30
DE60231068D1 (de) 2009-03-19
CA2457848A1 (en) 2003-03-20
IL160382A0 (en) 2004-07-25
PT1427420E (pt) 2006-10-31
CY1105189T1 (el) 2010-03-03
HRP20040241A2 (en) 2005-04-30
AU2006203428B2 (en) 2009-06-04
NZ531484A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
DK1378240T3 (da) Farmaceutiske præparater omfattende arsentrioxid til behandling af multipelt myelom
NO20062885L (no) Terapeufiske anti-IGFR1-antistoffkombinasjoner
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
DK1255537T3 (da) Farnesylproteintransferasehæmmere til behandling af brystcancer
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
EA200301104A1 (ru) Антиангиогенная комбинированная терапия для лечения онкологических заболеваний
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
ATE502025T1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
DK1567641T3 (da) Proaerolysin indeholdende proteaseaktiveringssekvenser og fremgangsmåder til anvendelse til behandling af prostatacancer.
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
CY1105189T1 (el) Χρηση συνδυασμου που πepιεχει 4-πυριδυλομεθυλοφθαλαζινες για τη θepαπεια του καρκινου
ATE456377T1 (de) Behandlung des metastasierenden karzinoms der niere
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
DE69912477D1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
ECSP044991A (es) Uso de 4-piridilmetil-ftalazinas para el tratamiento de cancer
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
DK1618116T3 (da) Ruthenium(II)-komplekser til behandling af tumorer
TW200626150A (en) Use of Epothilones in the treatment of bone metastasis
DE60016194D1 (de) Radioaktives cisplatin zur krebsbehandlung.
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей